Darren J. Wight

Dr. Darren J. Wight

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
AVAnkita Vaishampayan
Ankita Vaishampayan
AJAnne de Jong
Anne de Jong
DWDarren J. Wight
Darren J. Wight
JKJan Kok
Jan Kok
Elisabeth GrohmannElisabeth Grohmann
Elisabeth Grohmann
Methicillin-resistant Staphylococcus aureus (MRSA) has become an important cause of hospital-acquired infections worldwide. It is one of the most threatening pathogens due to its multi-drug resistance and strong biofilm-forming capacity. Thus, there is an urgent need for novel alternative strategies to combat bacterial infections. Recently, we demonstrated that a novel antimicrobial surface coating, AGXX®, consisting of micro-galvanic elements of the two noble metals, silver and ruthenium, surface-conditioned with ascorbic acid, efficiently inhibits MRSA growth. In this study, we demonstrated that the antimicrobial coating caused a significant reduction in biofilm formation (46%) of the clinical MRSA isolate, S. aureus 04-02981. To understand the molecular mechanism of the antimicrobial coating, we exposed S. aureus 04-02981 for different time-periods to the coating and investigated its molecular response via next-generation RNA-sequencing. A conventional antimicrobial silver coating served as a control. RNA-sequencing demonstrated down-regulation of many biofilm-associated genes and of genes related to virulence of S. aureus. The antimicrobial substance also down-regulated the two-component quorum-sensing system agr suggesting that it might interfere with quorum-sensing while diminishing biofilm formation in S. aureus 04-02981.

23 January 2009 in Transfusion
Verified
Journal Article
Closed access
PDF file
MJMichael Jones
Michael Jones
APAlexander H. Peden
Alexander H. Peden
HYHelen Yull
Helen Yull
DWDarren J. Wight
Darren J. Wight
MBMatthew T. Bishop
Matthew T. Bishop
MHMark W. Head
Mark W. Head

4 October 2012 in Retrovirology
Verified
Journal Article
Open access
PDF file
DWDarren J. Wight
Darren J. Wight
VBVirginie C Boucherit
Virginie C Boucherit
MNMirella Nader
Mirella Nader
David AllenDavid Allen
David Allen
ITIan A Taylor
Ian A Taylor
KBKate N Bishop
Kate N Bishop
Background: The Moloney murine leukaemia virus (Mo-MLV) gag gene encodes three main structural proteins, matrix, capsid and nucleocapsid and a protein called p12. In addition to its role during the late stages of infection, p12 has an essential, but undefined, function during early post-entry events. As these stages of retroviral infection remain poorly understood, we set out to investigate the function of p12. Results: Examination of the infectivity of Mo-MLV virus-like particles containing a mixture of wild type and mutant p12 revealed that the N- and C-terminal regions of p12 are sequentially acting domains, both required for p12 function, and that the N-terminal activity precedes the C-terminal activity in the viral life cycle. By creating a panel of p12 mutants in other gammaretroviruses, we showed that these domains are conserved in this retroviral genus. We also undertook a detailed mutational analysis of each domain, identifying residues essential for function. These data show that different regions of the N-terminal domain are necessary for infectivity in different gammaretroviruses, in stark contrast to the C-terminal domain where the same region is essential for all viruses. Moreover, chimeras between the p12 proteins of Mo-MLV and gibbon ape leukaemia virus revealed that the C-terminal domains are interchangeable whereas the N-terminal domains are not. Finally, we identified potential functions for each domain. We observed that particles with defects in the N-terminus of p12 were unable to abrogate restriction factors, implying that their cores were impaired. We further showed that defects in the C-terminal domain of p12 could be overcome by introducing a chromatin binding motif into the protein. Conclusions: Based on these data, we propose a model for p12 function where the N-terminus of p12 interacts with, and stabilizes, the viral core, allowing the C-terminus of p12 to tether the preintegration complex to host chromatin during mitosis, facilitating integration.

4 July 2017 in Viruses
Verified
Journal Article
Open access
PDF file
AKAhmed Kheimar
Ahmed Kheimar
RPRenato Lopes Previdelli
Renato Lopes Previdelli
DWDarren J. Wight
Darren J. Wight
BKBenedikt B. Kaufer
Benedikt B. Kaufer
Telomeres protect the ends of vertebrate chromosomes from deterioration and consist of tandem nucleotide repeats (TTAGGG)n that are associated with a number of proteins. Shortening of the telomeres occurs during genome replication, thereby limiting the replication potential of somatic cells. To counteract this shortening, vertebrates encode the telomerase complex that maintains telomere length in certain cell types via de novo addition of telomeric repeats. Several herpesviruses, including the highly oncogenic alphaherpesvirus Marek’s disease virus (MDV), harbor telomeric repeats (TMR) identical to the host telomere sequences at the ends of their linear genomes. These TMR facilitate the integration of the MDV genome into host telomeres during latency, allowing the virus to persist in the host for life. Integration into host telomeres is critical for disease and tumor induction by MDV, but also enables efficient reactivation of the integrated virus genome. In addition to the TMR, MDV also encodes a telomerase RNA subunit (vTR) that shares 88% sequence identity with the telomerase RNA in chicken (chTR). vTR is highly expressed during all stages of the virus lifecycle, enhances telomerase activity and plays an important role in MDV-induced tumor formation. This review will focus on the recent advances in understanding the role of viral TMR and vTR in MDV pathogenesis, integration and tumorigenesis.

1 December 2009 in Emerging Infectious Diseases
Verified
Journal Article
Open access
MJMichael Jones
Michael Jones
DWDarren J. Wight
Darren J. Wight
RBRona Barron
Rona Barron
MJMartin Jeffrey
Martin Jeffrey
JMJean Manson
Jean Manson
MHMark W. Head
Mark W. Head
To assess interspecies barriers to transmission of transmissible spongiform encephalopathies, we investigated the ability of disease-associated prion proteins (PrPd) to initiate conversion of the human normal cellular form of prion protein of the 3 major PRNP polymorphic variants in vitro. Protein misfolding cyclic amplification showed that conformation of PrPd partly determines host susceptibility.

3 December 2008 in NeuroReport
Verified
Journal Article
Closed access
MJMichael Jones
Michael Jones
APAlexander H. Peden
Alexander H. Peden
DWDarren J. Wight
Darren J. Wight
CPChristopher Prowse
Christopher Prowse
IMIan MacGregor
Ian MacGregor
MHMark W. Head
Mark W. Head
Prion protein type and codon 129 genotype are thought to be major determinants of susceptibility and phenotype in human prion diseases. Using an in-vitro system (protein misfolding cyclic amplification) we have attempted to model human prion protein conversion using the abnormal prion protein associated with each of the major sporadic Creutzfeldt–Jakob disease subtypes, in substrates containing the normal cellular form of the prion protein of each of the three possible human PRNP codon 129 polymorphic genotypes. The prion protein type is converted with fidelity in these amplification reactions, but the efficiency of conversion depends both on the methionine/valine polymorphic status of the sporadic Creutzfeldt–Jakob disease seed and substrate homogenate, and on the abnormal prion protein type.